Assessing the severity of the novel influenza A/H1N1 pandemic

A major concern about the emergence of the novel strain of influenza A/H1N1 is the severity of illness it causes. Tini Garske and colleagues propose methods to obtain accurate estimates of the case fatality ratio as the pandemic unfolds

[1]  R. Perez-Padilla,et al.  Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. , 2009, The New England journal of medicine.

[2]  G. Leung,et al.  Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease , 2005, American journal of epidemiology.

[3]  Rahul Raman,et al.  Transmission and Pathogenesis of Swine-Origin 2009 A(H1N1) Influenza Viruses in Ferrets and Mice , 2009, Science.

[4]  L. Finelli,et al.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.

[5]  Benjamin J Cowling,et al.  Non‐parametric estimation of the case fatality ratio with competing risks data: an application to Severe Acute Respiratory Syndrome (SARS) , 2006, Statistics in medicine.

[6]  Richard M Huggins,et al.  A Chain Multinomial Model for Estimating the Real-Time Fatality Rate of a Disease, with an Application to Severe Acute Respiratory Syndrome , 2005, American journal of epidemiology.

[7]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[8]  T. A. S. Group.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections , 1998, The Lancet.

[9]  Leming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .

[10]  Anne Chao,et al.  A comparison study of realtime fatality rates: severe acute respiratory syndrome in Hong Kong, Singapore, Taiwan, Toronto and Beijing, China , 2004, Journal of the Royal Statistical Society. Series A,.

[11]  G. Dennis Shanks,et al.  Deaths from Bacterial Pneumonia during 1918–19 Influenza Pandemic , 2008, Emerging infectious diseases.

[12]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[13]  S. Trottier,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.

[14]  A. Kumar,et al.  Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans , 2010 .

[15]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[16]  A. Gigli,et al.  Uncertainty of AIDS incubation time and its effects on back-calculation estimates. , 2000, Statistics in medicine.